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Abstract
Background: Physiological factors such as age and sex have been shown to be risk factors for adverse effects in
the liver, including liver diseases and drug-induced liver injury. Previously, we have reported age- and sex-related
significant differences in hepatic basal gene expression in rats during the life span that may be related to
susceptibility to such adverse effects. However, the underlying mechanisms of the gene expression changes were
not fully understood. In recent years, increasing evidence for epigenetic mechanisms of gene regulation has fueled
interest in the role of microRNAs (miRNAs) in toxicogenomics and biomarker discovery. We therefore proposed that
significant age and sex differences exist in baseline liver miRNA expression, and that comprehensive profiling of
miRNAs will provide insights into the epigenetic regulation of gene expression in rat liver.
Methods: To address this, liver tissues from male and female F344 rats were examined at 2, 5, 6, 8, 15, 21, 52, 78,
and 104 weeks of age for the expression of 677 unique miRNAs. Following data processing, predictive pathway
analysis was performed on selected miRNAs that exhibited prominent age and/or sex differences in expression.
Results: Of the 314 miRNAs found to be expressed, 214 were differentially expressed; 65 and 212 miRNAs showed
significant (false discovery rate (FDR) <5% and ≥1.5-fold change) sex- and age-related differences in expression,
respectively. Thirty-eight miRNAs showed 2-week-specific expression, of which 31 miRNAs were found to be
encoded within the Dlk1-Dio3 cluster located on chromosome 6. This cluster has been associated with tissue
proliferation and differentiation, and liver energy homeostasis in postnatal development. Predictive pathway
analysis linked sex-biased miRNA expression with sexually dimorphic molecular functions and toxicological
functions that may reflect sex differences in hepatic physiology and disease. The expression of miRNAs (miR-18a,
miR-99a, and miR-203, miR-451) was also found to associate with specific sexually dimorphic hepatic histopathology.
The expression of miRNAs involved in regulating cell death, cell proliferation, and cell cycle was found to change as the
rats matured from adult to old age.
Conclusions: Overall, significant age- and sex-related differences in liver miRNA expression were identified and
linked to histopathological findings and predicted functional pathways that may underlie susceptibilities to liver
toxicity and disease.
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Background
The liver plays a crucial role in metabolizing food and
drugs, and thus is of great toxicological importance.
Physiological factors such as age and sex have been
suggested as risk factors for liver diseases and drug-
induced liver injury (DILI). For example, anti-epileptic
drugs, such as carbamazepine and valproate, have been
associated with age-dependent susceptibilities to ad-
verse effects [1, 2]. Elderly patients who take carba-
mazepine showed an increased risk for adverse liver
reactions [3, 4], whereas younger patients taking val-
proate show increased risk for hepatotoxicity [5]. In
addition, other drugs, including erythromycin, halo-
thane, isoniazid, nitrofurantoin, and flucloxacillin, have
recently been associated with age-dependent increases
in adverse liver effects [6].
Moreover, sex-related differences in susceptibility to
DILI have been observed. For example, female patients
show increased incidence of anesthesia-related DILI
compared to males [7]. This sex-bias for anesthesia-
related DILI was also demonstrated in a mouse model,
which was further linked to an estrogen-dependent
pro-inflammatory response involving IL-6 suppression
of regulatory T-cells [8]. Clinical and epidemiological
studies suggest that females show more sensitivity to
adverse events after taking acetaminophen [9, 10], and
evidence supporting a general female-bias in DILI has
recently been reviewed [11]. However, a precise mech-
anism for the sex difference is not clearly understood.
Several other drugs exhibit sex-biased sensitivities to
DILI, but it is not clear whether males or females show
more sensitivity to DILI in general [12–14], suggesting
the sex bias may be drug-dependent. Establishment of
the underlying molecular basis for such age- and sex-
related susceptibilities to toxicities or diseases will en-
able safer use of such drugs.
We have previously reported marked age- and sex-
related differences in basal hepatic gene expression in
rats [15]. Differential expression was observed for over
3500 genes in a variety of different pathways. It is rec-
ognized that messenger RNA (mRNA) expression is
under the control of various transcriptional and post-
transcriptional mechanisms. miRNAs are short, non-
coding RNAs of 19–23 nucleotides in length that
regulate gene expression, typically by translational
repression of target mRNAs [16–19]. A single miRNA
may target a variety of mRNA transcripts and single
transcripts may be targeted by multiple miRNAs; thus,
their role in mRNA regulatory networks is complex.
miRNAs have been shown to influence diverse bio-
logical pathways and functions, with a prominent role
in various cancers [20, 21]. Furthermore, miRNA bio-
markers have shown promising utility in distinguish-
ing cancer types [22], detecting various tissue injuries
[23, 24], and making predictions regarding disease
outcomes [25]. Altered miRNA expression has been
reported in response to liver diseases and injuries, in-
cluding hepatitis C infection [26], non-alcoholic fatty
liver disease (NAFLD) [27], and DILI [28, 29]. Recent
studies suggest that miRNAs may play an important role
as biomarkers and tools in toxicogenomics [30–32].
A few miRNAs have been shown to exhibit age- [33–35]
and sex-dependent [36] patterns of expression. miR-34a
was among the first miRNAs to be characterized for its
role in aging and longevity in C. elegans [37, 38]. miR-34a
is a downstream target of p53 and its expression corre-
lates positively with age [39]. Similarly, increased liver
expression of miR-93, miR-214, and miR-669c has been
correlated with age. These miRNAs target glutathione-
S-transferases, which are crucial in protecting against
DILI-related oxidative stress [40]. Li et al. [33] have also
shown age-dependent increases in the expression of
miR-34a and miR-93, and that these miRNAs target
Mgst1, Sirt1, and Nrf2, three genes that encode pro-
teins important in the defense against oxidative stress,
a common feature in DILI. These studies demonstrate
the influence of miRNAs on pathways related to DILI
in an age-dependent manner and thus may help de-
velop a fuller understanding of age-related susceptibil-
ities to drug toxicities.
The roles of miRNAs in sexually dimorphic physiology
and diseases have recently been reviewed [36]. Sex dif-
ferences in expression can be regulated through both
genetic factors (e.g., X-chromosome encoded miRNAs)
and hormonal factors (e.g., sex steroids) [41]. The pri-
mary direct regulator of sex differences in gene expres-
sion in young adult and adult liver is growth hormone
[42]. In a carbon tetrachloride-induced liver fibrosis
mouse model, females exhibited protection against fi-
brosis compared to males, which was associated with
miR-29 family members. The miR-29 family members
are induced by estrogen and reduce fibrosis by inhi-
biting expression of collagens [43]. Additionally,
male-biased expression of miR-216a via the androgen
pathway has been reported in early hepatocarcinogen-
esis [44]. miR-216a has been shown to target and
decrease levels of Tslc1, whose expression is de-
creased in a number of tumors [45], thus implicating
the sex-biased expression of miR-216a in carcinogen-
esis. Taken together, there is evidence to suggest po-
tential roles for miRNAs in age- and sex-related
susceptibilities to liver diseases and toxicities.
Currently, no comprehensive reports characterizing
sex and age differences in miRNA expression in rat liver
tissue are available. In the present study, whole genome
expression profiles of miRNA in the liver of male and
female F344 rats during the life span were measured. Re-
sults showed substantial sex and age differences in basal
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liver miRNA expression levels that may have a role in
regulating expression of genes associated with hepatic
proliferation and differentiation, fibrosis, and steatosis.
These data will facilitate a better understanding of epigen-
etic regulation of sex- and age-related differences in hep-
atic gene expression and will help elucidate the molecular
basis underlying differential susceptibilities to toxicities at
different stages of life and between the sexes.
Methods
Animal study
All tissue samples came from a previously described
study [15] and were maintained at −80 °C prior to
utilization in the present project. Briefly, F344 rats were
obtained from the National Center for Toxicological
Research (NCTR) rat breeding colony. Male and female
animals were euthanized at 2, 5, 6, 8, 15, 21, 52, 78, and
104 weeks of age as previously described. Female estrus
cycles were not evaluated or synchronized. Animal care
and procedures were approved by the NCTR Institu-
tional Animal Care and Use Committee. Animals were
housed in polycarbonate cages with hardwood chip bed-
ding, two per cage, at 23 °C with a relative humidity of
approximately 50%. Rats were euthanized at the same
circadian time of day (between 0900 and 1100) by car-
bon dioxide asphyxiation. Liver tissue sections from rats
aged 52, 78, and 104 weeks of age were collected for
histological evaluation (Fig. 7). Tissue sections were placed
in 10% neutral buffered formalin followed by standard
paraffin embedding, sectioning, and hematoxylin and
eosin staining. Liver sections were evaluated for lesions,
including basophilic foci, hemorrhage, hyperplasia of the
bile duct, hepatocyte hypertrophy, lymphocyte infiltration,
chronic active inflammation, necrosis, portal vein throm-
bosis, and hepatocyte cytoplasmic vacuolization by staff
board-certified pathologists. Each lesion was graded for
severity using the following scale: 1 = minimal, 2 = mild,
3 = moderate, and 4 = marked. Liver sections were not
examined in the younger rats because lesions are only
generally found in older rats [46]. Contemporaneous
National Toxicology Program studies, using F344 rats
from the same source and living in the same environ-
mental conditions at NCTR (including feed) found no
basophilic foci, hyperplasia of the bile duct, or hepato-
cyte cytoplasmic vacuolization in rats of 6–7 weeks of
age (0/12 males and 0/12 females) and rats of 17–
18 weeks of age (0/24 males and 0/24 females) [47].
RNA isolation
Total RNA including the small RNA fraction were iso-
lated from ~30 mg frozen liver tissue that was ground
to a powder in liquid nitrogen and homogenized as pre-
viously described [15] following the manufacturer’s
protocol (Qiagen miRNeasy Mini Kit, Qiagen Inc.
Valencia, CA, USA). RNA samples were evaluated spec-
trophotometrically on a Nanodrop-1000 (ThermoFisher
Scientific, Waltham, MA, USA) by measuring the op-
tical density at 260 nm. RNA quality of each sample
was subsequently evaluated on RNA 6000 LabChips
using the Agilent 2100 Bioanalyzer (Agilent Technologies,
Palo Alto, CA, USA). RNA samples with RNA integrity
numbers (RINs) greater than 8.0 were used in miRNA
microarray experiments; the average RIN was 8.6.
Microarray experiments
Comprehensive miRNA expression profiling was per-
formed using single color (Cy3) Agilent Rat 8x15k
miRNA (version 16) microarrays and labeling reagents
according to the manufacturer’s protocol as previously
described [34]. A total of 88 arrays were used (n = 5 rat
liver RNA samples for all groups, except 5- and 104-
week-old males, where n = 4 rat liver RNA samples).
100 ng of total RNA, including the small RNA fraction,
was used as input. Agilent spike-in controls were used
to evaluate both labeling and hybridization efficiency,
and all were within acceptable ranges. BioRad Micro
Bio-Spin 6 columns were used to purify labeled probe
(BioRad Life Science Research, Hercules, CA) according
to manufacturer’s recommendation. Samples were proc-
essed on four separate days (four batches). To reduce
possible batch effects, samples from each age-sex group
were randomized among the four batches so that sam-
ples from each group were processed in three or four of
the batches, with the exception of the 8 week old female
group which was processed in two batches. Hybridized
miRNA microarrays were then scanned on an Agilent
DNA Microarray Scanner (Agilent Technologies) ac-
cording to the manufacturer’s instructions.
Microarray data processing
The procedure for processing the miRNA microarray
data in the current liver data set is identical to the pro-
cedure used in the previously published kidney miRNA
microarray data set [34]. This procedure and details per-
tinent to the liver data are described below for reference.
Microarray images (TIF) were analyzed using Feature
Extraction (FE) software (V10.7) from Agilent for pre-
liminary image quality control evaluations which utilized
the labeling and hybridization spike-in probes and fea-
tures. FE quality control metrics for each slide were
within the ranges designated as “good” or “excellent”.
Raw median intensities were calculated for each replicate
probe (n = 20 for each miRNA) in FE and used to gener-
ate a single value (Total Gene Signal, TGS) for each
miRNA. Individual data files were generated in FE for
each array (88 total files). The 88 individual files were
combined into a single file containing TGS data for each
array. TGS values of 0.1 represent a placeholder
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indicating miRNA signal below the level of detection for
the assay, equivalent to “not expressed”. Values of 0.1
were subsequently replaced by the global minimum in-
tensity value (1.84) across all arrays. A single file con-
taining processed TGS values was used as input for
further processing in SAS 9.3 (SAS Institute Inc., Cary,
NC). SAS was used to remove control spots and target
spot redundancy/replication. The Agilent Rat 8x15k
miRNA microarray (v16) contains 15,744 array spots;
2204 control spots were removed, leaving 13,540 spots
of target miRNA probes (677 unique miRNAs x 20 repli-
cates per miRNA). Redundant replicates containing
identical TGS values were removed for each miRNA,
resulting in data for 677 unique miRNAs. The 363 non-
expressed miRNAs (miRNAs with original unprocessed
TGS values of 0.1 across all arrays) were discarded, leav-
ing 314 unique miRNAs expressed in at least one rat
liver sample. The TGS values (raw intensities) of these
314 “expressed” miRNAs were then transformed to log2
values in SAS followed by 75th percentile normalization.
To prevent generating false fold differences from
placeholders, transformed 1.84 values were replaced by
0.012 (lowest transformed value among all samples with
measured values).
Microarray statistical analysis
Statistical analysis was performed in SAS using a gen-
eralized linear model procedure (proc glm). Model
(RandommodelANOVA) and estimate statements were
used to perform ANOVA and pairwise comparisons
using least square method to measure the significance
of group differences using log2 intensities as the dependent
variable and age or sex as independent variables. Signifi-
cant age differences in miRNA expression were calculated
separately for males and females. Significant sex differ-
ences in miRNA expression were calculated at each
age. The ANOVA p value and p value from pairwise
tests were adjusted to false discovery rate (FDR). The
magnitude of group differences was calculated as the
difference of average log2 intensities; the anti-log of the
resulting value was used as the fold change value be-
tween groups. When group absolute fold changes were
greater than or equal to 1.5 and FDR for ANOVA as
well as pairwise tests were significant (p < 0.05), miR-
NAs were determined to be differentially expressed by
age. Differential expression by sex was determined
using absolute fold changes greater than or equal to 1.5
between sexes of the same age and a pairwise t test with
FDR < 5%. Normalized intensity values (normalized
TGS) were subsequently uploaded into ArrayTrack
[48], the Food and Drug Administration’s relational
database for genomic data storage, processing, analysis,
and visualization that was created at NCTR [49]. Array-
Track is available for free [50].
Principal component analysis (PCA) and k-means clus-
ter analysis were performed in ArrayTrack on log2-
transformed, normalized intensity values.
Raw expression data, as well as processed data, were
deposited in Gene Expression Omnibus (Accession ID:
GSE65169).
Taqman qPCR experiments
Quantitative PCR (qPCR) experiments were carried out
using Taqman miRNA assays. 5 ng of total RNA from
each sample (n = 5 per group) was used in a 15-μl re-
verse transcription reaction using the Taqman miRNA
Reverse Transcription Kit (Life Technologies, Grand
Island, NY) along with miRNA-specific primers accord-
ing to manufacturer’s protocol. The reverse transcription
product (1.33 μl) was subsequently used in a 20-μl Taq-
man MicroRNA Assay reaction with predesigned
miRNA-specific probes. The qPCR reactions were per-
formed in MicroAmp Optical 384-well reaction plates
on the ABI 7900HT real-time PCR detection system
(ThermoFisher). Taqman assays were performed for
miR-154* (Assay ID: 000478), miR-29b (Assay ID:
000413), miR-96 (Assay ID: 000186), and miR-34a
(Assay ID: 000425) due to their age- and/or sex-related
expression differences. U6 snRNA (Assay ID: 001973)
was used as endogenous control in the Taqman assay
and ΔCt was further normalized to the global average of
each miRNA using the ΔΔCt method. The average log2
relative expression per group of qPCR and microarray
data are displayed for miR-29b, miR-34a, miR-96, and
miR-154* such that the global average expression for
qPCR (n = 5) and microarray data (n = 4 or 5) is equal to
zero. Sex differences in the qPCR data were tested for
statistical significance using a simple t test (p < 0.05).
Taqman qPCR and microarray expression profiles for
each miRNA were compared using a Pearson correlation
coefficient (r) in Microsoft Excel.
miRNA pathway analysis
QIAGEN’s Ingenuity Pathway Analysis software (IPA;
QIAGEN, Redwood City, CA) was used to associate dif-
ferentially expressed miRNAs with their target mRNAs,
and pathway analysis. Briefly, lists of differentially
expressed miRNAs (using the Agilent probe identifiers)
were imported into IPA, and the miRNA target filter
function in IPA was used to identify their corresponding
mRNA targets. The analysis was restricted to experi-
mentally observed interactions retrieved from TarBase
[51], miRecords [52], and curated peer-reviewed litera-
ture. The output of this analysis was exported as an
Excel file, duplicate mRNA targets removed, and the file
of mRNA targets uploaded to IPA. These lists of target
mRNAs were then examined for over-representation in
biological pathways curated in IPA using the Core
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Analysis option. All settings were default settings ex-
cept the species selected was rat. Molecular and cellular
functions, as well as physiological system development
and function under the diseases and functions tab were
identified. Tox functions, including only hepatotoxicity,
were examined as well. Pathways and functions were
considered significant if there were at least three
mRNAs in the pathway/function, and Fisher’s exact test
p value was less than 10−3. The analysis was limited to
rat-specific data except for analysis of the 2-week-
specific expression class where the more abundant hu-
man data was included.
Results
Hepatic miRNA profiles change during the rat life span
The microarrays allowed examination of the expression
levels of 677 unique miRNAs. More than half (363 miR-
NAs) showed no detectable expression at any age or sex
and were removed from further analysis. The remaining
314 miRNAs showed a detectable expression level in at
least one sample. An ANOVA with an FDR <5% was
used to identify age-dependent differences in the expres-
sion of the 314 expressed miRNAs in males and females,
independently. Subsequently, post hoc multiple compari-
sons tests (p < 0.05) with a fold change ≥1.5-fold
between age groups, identified 176 and 171 miRNAs
that showed differential expression by age in females
and males, respectively, for a total of 212 age-affected
miRNAs in either sex (Additional file 1). miRNAs show-
ing significant sex differences were identified by compar-
ing males and females at each age using a pairwise t test
with FDR < 5% and fold change ≥1.5 between the sexes.
The application of these criteria identified 65 unique
miRNAs that showed sexually dimorphic expression in
at least one age. In combination, a total of 214 miRNAs
(Additional file 2) were differentially expressed by age
and/or sex with 63 miRNAs showing both age and sex
differences. These 214 miRNAs were used in further
analyses. The expression of more miRNAs was impacted
by age than sex, and most sex-related differentially
expressed miRNAs (DEMs; 97%; 63/65) also showed an
age effect.
PCA, utilizing the expression profiles of these 214
DEMs, was used to evaluate the relationships among the
88 liver samples (Fig. 1). PC1 accounted for a large pro-
portion of the variability (50.7%). Individual animals gen-
erally divided into two groups consisting of 2-week-old
animals (Fig. 1; blue) and all remaining age groups, sug-
gesting a distinct miRNA expression pattern at 2 weeks




















Fig. 1 PCA plot of differentially expressed miRNA profiles of 88 rat liver samples. Normalized log2 intensity values for 214 miRNAs that were
differentially expressed by age and/or sex in livers of rats of nine ages and both sexes are plotted. Each sphere represents the composite DEM
profile from a single animal. Colors represent age groups. Black vertices indicate female animals; males have none
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between 5 and 21-week-old animals and 52 to 104-
week-old animals. Within the 2-week-old group of ani-
mals, a slight but consistent division between males (on
the left) and females (on the right) was observed. Aside
from this slight sexually dimorphic pattern at 2 weeks of
age, the remaining age groups showed little to no evi-
dence of sex differences in the PCA plot.
After establishing the global relationships between
groups and replicates, k-means cluster analysis was used
to visualize patterns among the individual miRNA pro-
files using the 214 DEMs (Fig. 2; cluster members are
shown in Additional file 2). An initial number of k = 10
clusters was used as an estimate of the number of large-
scale expression profiles present within the miRNA data.
Three trends in the k-means cluster analysis were ob-
served. First, miRNAs generally clustered according to
normalized expression level, with highly expressed miR-
NAs grouping with other highly expressed miRNAs (e.g.,
clusters 8–10), and low/medium expressed miRNAs with
others showing low/medium expression (e.g., clusters 1,
4, 5, and 6). Secondly, miRNAs generally maintained
stable expression patterns across age and sex (e.g., clus-
ters 4–10). Thirdly, clusters 2 and 3 diverged from this
stable expression profile with a unique 2-week-specific
expression pattern in both sexes, followed by little to
no expression at subsequent ages. There were a total of
38 miRNAs in clusters 2 and 3 which exhibited a 2-
week-specific expression pattern. miRNAs in cluster 3
exhibited the greatest difference in expression between
2 weeks of age and all subsequent ages. Within cluster
3, male and female animals, on average, showed a 28-
and 53-fold difference, respectively, in expression
between 2 weeks of age and all subsequent ages. Thus,
k-means cluster analysis helped identify specific miR-
NAs that account for the prominent age differences ob-
served in the PCA.
Fig. 2 Heatmap of k-means cluster analysis of 214 differentially expressed miRNAs in 88 rat liver samples. Normalized log2 intensity values for 214
miRNAs that were differentially expressed by age and/or sex in liver of rats of nine ages and both sexes were used for k-means cluster analysis
where k = 10 clusters. Intensity scale is shown on the upper right with red indicating high expression and black indicating low expression. Clusters
are identified on the left and miRNAs identified in Additional file 2. Age (in weeks) is along bottom.
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Sex differences in expression of miRNAs
Sex different expression of miRNAs was evaluated at
each age (t test with FDR < 5% and fold change ≥ 1.5)
and shown in Fig. 3a (females) and Fig. 3b (males), along
with the expression fold-differences. A total of 32 miR-
NAs showed significant female-biased expression at any
age while 33 miRNAs exhibited male-biased expression.
There was no overlap between the 32 female-biased
miRNAs and the 33 male-biased miRNAs. While most
of the sex-biased miRNAs occurred at just a single age
(54 of the 65 sex-biased miRNAs), 11 (5 female and 6
male) were present at more than one age. Female-
biased expression of miR-29b and miR-152 occurred
from 15 to 78 weeks of age while male-biased expres-
sion of miR-125b-5p and miR-99a occurred during
this same age span. A single miRNA (miR-183)
showed sex-biased expression at 104 weeks of age and
was expressed at levels 17.2 times higher in males than
females. Twenty-nine miRNAs were expressed in a
sex-biased manner in 2-week-old animals (12 female-
biased, 17 male-biased), with differences of 1.5- to 4.8-
fold (average = 2.0-fold difference). There were fewer
miRNAs showing sex-biased expression at subsequent
ages: 4 miRNAs at 8 weeks (3 female, 1 male), 15
miRNAs at 15 weeks (8 female, 7 male), 20 miRNAs at
21 weeks (11 female and 9 male), 9 miRNAs at
52 weeks (2 female and 7 male), and 9 at 78 weeks (5
female and 4 male). Animals between 5 and 6 weeks of
age showed no significant sex-biased miRNA expres-
sion. Thus, most sex-biased miRNA expression
occurred at a single age and occurred predominantly
at 2 (29 miRNAs), 15 (15 miRNAs), and 21 (20 miR-
NAs) weeks of age. Persistent sex-biased expression of
4 miRNAs (miRNAs 29b, 152, 125b-5p, and 99a)
occurred in adults at 15–78 weeks of age, with expres-
sion fold-differences between the sexes of 1.6–2.9. The
sex-biased expression of 9 miRNAs in both sexes dur-
ing the life span is shown in Fig. 4, with panels a
through d showing female-biased miRNA expression,
and panels e through i showing male-biased expres-
sion of miRNAs.
Age differences in expression of miRNAs
Examination of the PCA (Fig. 1) identified a large differ-
ence in liver miRNA expression profiles between 2 weeks
of age and the other ages along principal component
(PC) 1. In addition, there was a smaller, and incomplete,































































































































































2 1.5 1.5 1.6 1.6 1.6 1.6 1.7 1.7 1.8 1.8 1.8 1.9
5
6
8 8.7 6.8 3.7
15 2.3 4.3 8.3 2.1 9.9 2.0 2.1 5.1
21 1.7 7.7 7.6 9.2 1.5 1.5 1.6 1.6 1.7 1.8 2.0
52 2.3 2.9



























































































































































15 4.4 3.1 2.1 1.8 1.7 1.6 1.6
21 14.3 1.7 1.6 1.5 1.6 1.5 4.0 1.8 2.2
52 2.3 2.2 2.2 7.2 1.7 1.7 1.6
78 1.8 1.9 1.9 5.4
104 17.2
Fig. 3 Sex-biased miRNA expression at nine ages in the livers of rats. Sex-biased miRNAs are displayed along the horizontal axis for females (a)
and males (b). Age of the rats is shown on the vertical axis. Numbers indicate fold-difference in expression of the indicated miRNA, female/male
(a) and male/female (b).
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age samples generally grouping away from the more
tightly clustered samples from the older ages (52–
104 weeks of age). Also, as described below, hepatic
histopathology was seen in the livers of the older rats
(52–104 weeks of age) and not in the livers of the 5–
21 week old rats. For these reasons, the 9 age groups
were divided into 3 age classes, young (2 weeks of age),
adult (5 to 21 weeks of age) and old (52 to 104 weeks of
age), for identification of hepatic age-related DEMs.
Age-related DEMs were identified independently in females
and males using a t test with an FDR of <5% and requiring
a fold change difference of at least 1.5. When comparing
young to adult, 159 male DEMs and 131 female DEMs
(Fig. 5a) were identified as age-related DEMs. Among these,
115 were in common, suggesting similar miRNA ex-
pression patterns in males and females. Indeed, 88% of
the female DEMs were also differentially expressed in
males. There were also large numbers of DEMs when
comparing young to old rats, 161 in males and 148 in
females, with 125 (>77%) in common (Fig. 5b). This in-
dicates that there are large differences in the liver
miRNA profiles between young rats and adult and old
rats, and much smaller differences between adult and
old rats. Comparing the miRNA liver expression pro-
files between adult and old rats identified only 17
DEMs in males and 14 in females, of which 6 were in
common (Fig. 5c). The miRNAs in each comparison
are shown in Additional file 3.
As noted above, k-means cluster analysis identified
38 miRNAs (clusters 2 and 3 in Fig. 2) that showed a
2-week-specific expression pattern, i.e., there was high
expression in the livers of 2-week-old rats but low/un-
detectable expression at later ages (expression values
are shown in Additional file 4). The expression of one
of these miRNAs (miR-376b-3p) through the life span
is shown in Fig. 4. In males, the expression of miR-
376b-3p at 2 weeks of age was >320-fold higher than
the average expression at all other ages, while in
females it was >150-fold higher. In males, 35 of the 38
miRNAs were expressed at >10-fold greater levels in 2-
week-old animals than at all subsequent ages. In
females, 28 of the 38 miRNAs were expressed at >10-
fold greater levels in 2-week-old animals than at all










Fig. 4 Individual miRNA expression profiles. The expressions of DEMs exhibiting significant differential expression by sex and/or age are plotted
(a–i). Y-axis represents normalized intensity level; X-axis represents age in weeks. Red and blue bars represent female and male group averages,
respectively, with standard errors of the means shown. An asterisk indicates ages at which a significant sex difference (≥1.5-fold change and t test
with FDR <5%) is present
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higher than female expression for all except one (miR-
675*) of the two-week-specific miRNAs. On average,
the expression of these 38 hepatic miRNAs was 1.9-
fold higher in males than in females at 2 weeks of age.
The genes for 31 of the 38 miRNAs are located on rat
chromosome 6 (see Additional file 2 and Additional file 4).
Verification of microarray data by qPCR
Four DEMs that showed significant sex and/or age dif-
ferences by microarray analysis (miR-29b, miR-96, miR-
154*, and miR-34a) were selected for verification by
Taqman qPCR assays. Pearson correlation coefficients
for the measurements by the two methods for the four
miRNAs ranged from 0.835 to 0.966 (shown in Fig. 6),
suggesting good agreement between the two methods
of expression analysis. Measurement of miR-29b
expression by microarray showed female-biased expres-
sion at 15, 21, 52, and 78 weeks of age. Significant (p <
0.05) sex difference was confirmed by qPCR for miR-
29b only at 52 weeks of age (female > male, Fig. 6a).
Microarray data for miR-96 showed male-biased ex-
pression at 21, 52, and 78 weeks of age. Taqman qPCR
results confirmed this male-biased miR-96 expression
at 78 weeks of age and additionally at 104 weeks of age
(Fig. 6b). By microarray measurement, miR-154*
showed 156- and 383-fold increased expression at
2 weeks of age compared to the average expression at
all subsequent ages in females and males, respectively.
This large 2-week-specific expression difference was
verified in the qPCR data, which showed 2-week ex-
pression differences of 1212-fold and 4169-fold in
females and males (Fig. 6c), respectively. The larger fold
changes determined by qPCR may be due to the larger
dynamic range of the qPCR assay. In addition, the sig-
nificant male-biased expression at 2 weeks of age was
confirmed by qPCR. Significant age-related increases in
miR-34a expression (7.1- and 13.2-fold maximum age
difference in females and males, respectively; micro-
array data) were also confirmed by qPCR, which
showed significant (p < 0.05) 7.2- and 8.7-fold differ-
ences in expression across the life span in females and
males, respectively (Fig. 6d). Thus, there was good cor-
relation between the expression levels determined by
microarray and qPCR, although expression differences
of <2-fold were not always confirmed.
Potential pathways and functions of DEMs
Potential mRNA targets of the DEMs were identified
using Ingenuity Pathway Analysis software, restricting
the analysis to experimentally validated interactions re-
trieved from TarBase, miRecords, and curated from the
peer-reviewed literature. The predicted mRNA targets
were then examined for over-representation in biological




Fig. 5 Age differences in expression of miRNAs. Venn diagrams
showing the number of differentially expressed hepatic miRNAs
between different age groups of male (M) and female (F) rats. a
Differences and commonalities between young (Y; 2 weeks of age)
and adult (A; 5–21 weeks of age). b Differences and commonalities
between young (Y) and old (O; 52–104 weeks of age). c Differences
and commonalities between adult (A) and old (O)
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2-week-old-specific hepatic miRNA expression
38 miRNAs were identified in the k-means cluster
analysis as being expressed in the livers of pre-
weaning 2-week-old rats and expressed at reduced
levels or not detectable levels at all subsequent ages
(Fig. 2, clusters 2 and 3; Additional file 4). Table 1
shows the 38 miRNAs in this 2-week-specific class
along with the mRNA targets and associated path-
ways/functions where the mRNAs were significantly
enriched. A relatively small number of mRNA targets
(Capn8, Cntn4, Onecut1, Tagln, and Vim) was identi-
fied using rat-specific data from IPA and no significant
pathways were identified. Human-specific miRNA-
mRNA association data were, therefore, included in
the analysis and this expanded the mRNA targets by 5,
giving a total of 10 mRNA targets for the 38 miRNAs.
Only 6 of the miRNAs had associated mRNAs, and
these mRNAs were significantly represented in the
molecular functions: cellular development, cellular
growth and maintenance, cellular growth and prolifer-
ation, cell morphology, and cell-to-cell signaling.
Notably, 3 of the mRNAs (BCL6, PRDM1, and XBP1),
all targets of miR-127, were associated with the
hematological system.
Fig. 6 Quantitative PCR verification of microarray results. The expression of select miRNAs was evaluated by Taqman quantitative PCR (qPCR)
(a–d). The y-axis represents relative miRNA expression; the x-axis represents age of rat when euthanized. The red and blue lines represent female
and male, respectively (■: PCR; □: microarray). Standard errors of the means are shown at each age except for MiR-154* (panel c) where it was
undetectable in some assays. The Pearson correlation coefficient (R) is listed in the figure to show the concordance between the two methods
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Table 1 mRNA targets and pathways/functions associated with differentially expressed miRNAs
miRNA class miRNAs in classa # of miRNAs
in class






miR-127, miR-127*, miR-136, miR-136*,
miR-154, miR-154*, miR-299, miR-300-3p,
miR-322*, miR-329, miR-337, miR-337*,
miR-341, miR-3563-3p, miR-369-5p,
miR-376a, miR-376b-3p, miR-376b-5p,
miR-376c, miR-379, miR-381, miR-382,
miR-409-5p, miR-410, miR-411, miR-411*,
miR-431, miR-434, miR-434*, miR-455,
miR-483, miR-487b, miR-495, miR-541,
miR-542-3p, miR-542-5p, miR-582,
miR-675*
38 BCL6, CAPN8, CNTN4, ONECUT1,














miR-100, miR-107, miR-125b-5p, miR-
139-3p, miR-144, miR-151, miR-152,
miR-191*, miR-200b, miR-203, miR-21,
miR-221, miR-27b, miR-290, miR-29b,
miR-326, miR-339-3p, miR-340-3p,
miR-34b, miR-374, miR-425, miR-466b-2*,
miR-505*, miR-532-3p, miR-598-3p,
miR-652, miR-802, miR-96, miR-99a,
miR-99a*
30 Acvr2a, Adamts1, Adcy6, Adora1,
Adora2b, Akap6, Apaf1, Aqp5,
Arc, Axin2, B3galt4, Bace1, Bak1,
Bcl2, Bcl2l11, Bmf, Bmpr2, Bnip3l,
Btg2, Capn8, Casp6, Casp7,
Cbln2, Cbx7, Ccnd1, Ccne1,
Cd276, Cdc25a, Cdca4, Cdk6,
Cdkn1a, Cdkn1b, Cdkn2a,
Cebpg, Celsr2, Cntn4, Col1a1,
Col1a2, Col3a1, Col4a1, Col5a3,
Crkl, Cyp1a1, Cyp1b1, Ddit4,
Dicer1, Dio3, Dll1, Dnmt1,
Dnmt3a, Dnmt3b, Dusp2, E2f5,
Elmo2, Erbb2, Erbb3, Errfi1, Esr1,
Fadd, Fam3c, Fbn1, Fgf16, Fgfr3,
Fos, Golph3, Gpr160, H3f3b,
Hdac4, Hipk3, Htr1b, Icam1, Icos,
Id1, Id2, Id3, Igf1r, Igfbp3, Il1rn,
Irs1, Jag1, Kcnj16, Kit, Klf15,
Lamc1, Madd, Map2k1, Mapk1,
Mcl1, Met, Mgst1, Mitf, Mmp13,
Mmp9, Myc, Myrip, Nfib, Notch1,
Notch2, Nr1i2, Nr4a1, Odc1,
Pdcd4, Peli1, Pex7, Phb, Pigr,
Pik3r1, Plag1, Plk1, Pparg,
Ppp2r2a, Pten, Ptprd, Rere,
Runx1, Rxra, Ryk, Serpinb5,
Sgpl1, Slc16a10, Smad3, Smad4,
Smad5, Smo, Socs3, Sod2, Sox5,
Sp1, Sparc, Spry2, Srm, Ssr3,
St14, St18, Stx1a, Syt4, Tagln,
Tdg, Tgfb3, Timp3, Tp53, Tpm1,
















Sex difference in old miR-125b-5p, miR-152, miR-183,
miR-29b, miR-31, miR-31*, miR-340-5p,
miR-374, miR-494, miR-92a, miR-96,
miR-99a, miR-99a*
13 Acvr2a, Adamts1, Adcy6, Aqp5,
B3galt4, Bace1, Bak1, Bcl2l11,
Bmf, Bmpr2, Btrc, Casp6, Casp7,
Casr, Cbln2, Cbx7, Cd276,
Cdc25a, Cdk6, Cdkn2a, Cebpg,
Celsr2, Col1a1, Col1a2, Col3a1,
Col4a1, Col5a3, Cyp1a1, Dicer1,
Dio3, Dnmt1, Dnmt3a, Dnmt3b,
Dusp2, Erbb2, Erbb3, Fbn1,
Fgf16, Fgfr3, Gpr160, H3f3b,
Hdac4, Hif1a, Hipk3, Hmox1,
Htr1b, Id1, Id2, Id3, Igf1r, Igfbp3,
Il1rn, Irs1, Lamc1, Map2k4, Mcl1,
Mitf, Myrip, Nr1i2, Pdgfb, Pigr,
Pik3r1, Plk1, Ppp2r2a, Pten, Ryk,
Scn3a, Sgpl1, Smo, Sp1, Sparc,
St18, Tdg, Tgfb3, Tp53, Tpm1,












adults and old (male)
miR-125b-5p, miR-146b, miR-200b,
miR-203, miR-221, miR-29a, miR-29b,
miR-29c, miR-324-5p, miR-34a, miR-375,
17 Acvr2a, Adamts1, Adipor2,
Axin2, B3galt4, Bace1, Bak1, Bcl2,
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Sex different miRNA expression in the liver of adult
and old rats
As shown in Fig. 3, 30 hepatic miRNAs were found to
be differentially expressed between the sexes in adults
(5–21 weeks of age), and 13 were found to be differen-
tially expressed in old rats (52–104 weeks of age). Table 1
shows the sex different miRNAs in these two age groups,
as well as the target mRNAs and the significantly af-
fected pathways/functions. Target mRNA information
was available for at least half of the miRNAs for these
two groups (15/30 for the adults and 9/13 for old),
resulting in 149 mRNA targets in the adults and 81
mRNA targets in the old group. The top five most sig-
nificant molecular functions affected by the mRNA tar-
gets of the sexually dimorphic miRNAs were identical
between the two age groups: cell death and survival,
cellular growth and proliferation, cellular development,
gene expression, and cell cycle. These mRNA targets
also appeared to be involved in liver toxicology func-
tions, with more significant effects in the adults (signifi-
cantly affected functions included liver necrosis, liver
proliferation, liver fibrosis, hepatocellular carcinoma,
and liver hyperplasia) than old rats (significantly af-
fected functions included only liver necrosis).
Table 1 mRNA targets and pathways/functions associated with differentially expressed miRNAs (Continued)
miR-455*, miR-466b-2*, miR-598-3p,
miR-802, miR-99a, miR-99a*
C1qbp, Casp6, Casp7, Cbln2,
Cbx7, Ccna2, Ccnd1, Cd276,
Cdc25a, Cdk6, Cdkn1b, Cdkn2a,
Cebpg, Cfh, Col1a1, Col1a2,
Col3a1, Col4a1, Col5a3, Cxcr4,
Cyp1a1, Ddit4, Dicer1, Dio3, Dll1,
Dnmt3a, Dnmt3b, Dusp2, E2f5,
Elmo2, Erbb2, Erbb3, Errfi1, Esr1,
Fadd, Fbn1, Fgf16, Fgfr3, Fos,
Gpr160, H3f3b, Hdac4, Icam1,
Id1, Id2, Id3, Igf1r, Igfbp3, Il1rn,
Irak2, Jag1, Jak2, Kif22, Kit,
Lamc1, Ltb, Map2k1, Mcl1, Met,
Mettl7a, Mmp16, Mtpn, Myc,
Notch1, Notch2, Pa2g4, Pigr,
Pik3r1, Plekha4, Plk1, Ppp2r2a,
Ptprd, Rere, Sdcbp2, Sgpl1, Smo,
Socs3, Sod2, Sp1, Sparc, St18,
Stat1, Tagln, Tdg, Tgfb3,
Timeless, Tp53, Tpm1, Tspan8,

















miR-1, miR-133b, miR-182, miR-183,
miR-18a, miR-206, miR-29a, miR-29b,
miR-29c, miR-34a, miR-375, miR-466b,
miR-466b-2*, miR-96
14 Acvr2a, Adar, Adcy6, Adipor2,
Aqp5, Arcn1, Arf3, Arf4,
Arhgap29, Atp6v1b2, Axin2, Axl,
Bace1, Bcl2, Bcl2l11, Bdnf, Blcap,
Btrc, C1qbp, Calm3, Cand1,
Cap1, Ccnd1, Cd276, Cdc42,
Cdk6, Cdk9, Celsr2, Clcn3, Cnn3,
Col1a1, Col1a2, Col3a1, Col4a1,
Col5a3, Ctgf, Ddx5, Dll1,
Dnmt3a, Dnmt3b, Dusp2, E2f5,
Esr1, Fbln2, Fbn1, Fstl1, Gja1,
H3f3b, Hand2, Hdac4, Htr1b,
Igf1, Igf1r, Irs1, Jag1, Jak2, Kcnj2,
Klf15, Lamc1, Lasp1, Lin7c, Lztfl1,
Map2k1, Mcl1, Met, Mitf, Mmd,
Mtpn, Myc, Myrip, Nfatc4,
Notch1, Notch2, Notch3, Oat,
Pdcd4, Pik3r1, Pim1, Pitx3, Pola1,
Pom121, Rabl2a, RGD1359334,
Rhoa, Rnf138, Runx2, Ryk, Sdc4,
Serpinb5, Sh2d4a, Slc25a30, Sp1,
Sparc, Srxn1, Tac1, Tagln, Tagln2,
Tdg, Tdp1, Tgfb3, Thbs1, Timp3,
Tns4, Tpm1, Trappc3, Trim2,
Tspan4, Uhmk1, Usp1, Utrn,













amiRNAs in italics have known mRNA targets in the IPA database
bDerived from rat-specific miRNA-mRNA associations except for the 2-week-specific miRNA class, which included both rat- and human-specific miRNA-mRNA
associations in IPA
cFrom IPA pathway/function analysis with criteria of at least three mRNAs per pathway/function and a Fisher’s exact test p value < 10−3
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Hepatic miRNA expression differences between adult
and old rats
As shown in Fig. 5c and Additional file 3, there were 25
miRNAs whose hepatic expression differed between
adult (5–21 weeks of age) and old (52–104 weeks of age)
rats, with 17 different between adult males and old
males, and 14 different between adult females and old
females. The expression of 6 of these miRNAs differed
between adult and old rats in both sexes; the expression
of 11 differed only in male rats, and the expression of 8
differed only in female rats. Table 1 shows these age
different miRNAs in males and females, along with the
target mRNAs and significantly affected pathways/func-
tions. Target mRNA information was available for
about half of the miRNAs (8/17 for the males and 8/14
for the females), resulting in 109 mRNA targets for
males and 115 mRNA targets for females. The top five
molecular functions were identical for both the males and
the females (cell death and survival, cellular growth and
proliferation, gene expression, cellular development, and
cell cycle), and were the same as found for the sex differ-
ences in adults and sex differences in old rats. The liver
toxicological function differences between adult and old
rats were similar in each sex, with liver necrosis and liver
proliferation functions found in both sexes. There were
additional significant liver toxicological function differences
between adult and old males that were not seen between
adult and old females, and these included hepatocellular
carcinoma, liver hyperplasia, and liver fibrosis. The
similarity in pathway/function differences between
adult and old in both sexes may be the result of the
large overlap in mRNA targets; 47 mRNA targets were
in common between the sexes.
Association of hepatic miRNA expression with liver
histopathology
Liver histology sections were examined for standard
pathological findings at 52, 78, and 104 weeks of age.
Sex bias in the incidence of three types of lesions was
observed (Table 2). These included basophilic focus,
hyperplasia of the bile duct, and vacuolization in hepato-
cyte cytoplasm. Examples of the histological presentation
of these lesions are shown in Fig. 7. Female-biased inci-
dence of basophilic foci was evident at 78 weeks (3 of 8
females showed the lesion compared to 0 of 8 males)
and 104 weeks (12 of 16 females compared to 0 of 14
males). As is typical for histopathological findings of
basophilic foci, no severity score was provided [53].
Basophilic foci are considered pre-neoplastic lesions;
however, no neoplasms were observed in any female ani-
mals. One neoplastic lesion (classified as hepatocellular
adenoma), however, was observed in a male animal at
104 weeks of age. This is consistent with the slightly
higher incidence rate for hepatocellular adenoma in
normal males (2.3%) compared to females (0.44%) at two
years of age, according to National Toxicology Program
historical control animal data for F344 rats [54]. Male-
biased incidence of hyperplasia of the bile duct was ob-
served at 52 weeks of age (8 of 10 males compared to 0
of 10 females), 78 weeks of age (7 of 8 males compared
to 2 of 8 females), and 104 weeks of age (10 of 14 males
compared to 2 of 16 females). Severity scores among
animals showing the lesion ranged from minimal to
mild in all cases. Male-specific incidence of hepatocyte
cytoplasm vacuolization was observed at 52 weeks of
age (5 of 10 males), 78 weeks of age (2 of 8 males), and
104 weeks of age (1 of 14 males) compared to zero inci-
dence in females of the same ages. Average severity
scores for this lesion also ranged from minimal to mild,
with one case of moderate (78 weeks) and one case of
marked (104 weeks). All findings were considered com-
mon for F344 rats of these ages.
As can be seen in Table 2, there is a substantial sex
difference in the prevalence of basophilic foci in the
livers of 78- and 104-week-old rats, with females show-
ing this histopathology while males did not. The histo-
pathology was not observed in males or females of
52 weeks of age, or in males of 78 or 104 weeks of age.
Basophilic foci were not found (0/12 males and 0/12
females at 6–7 week of age and 0/24 males and 0/24
females at 17–18 weeks of age) in contemporaneous
studies at NCTR using F344 rats from the same colony
and living in the same environmental conditions at
NCTR [47]. Using the expression level from 5 to
21 weeks of age (adults) as a baseline where no liver
histopathology was observed, the fold change in ex-
pression of each miRNA was calculated at 52, 78, and
104 weeks of age for each sex separately. miRNAs were
excluded if the expression value was less than 0.3 (60th
percentile of expression level distribution; approxi-
mately 40% of expression values were undetectable) in
all age groups. Significantly changed expression was
defined as p < 0.05 and fold change ≥ 1.5 between the
adult age group and 52, 78, or 104 weeks of age groups
for each sex independently. A total of 43 miRNAs met
these criteria and are shown in Additional file 5. The
expression of two miRNAs was associated with the
presence and absence of basophilic foci, miR-18a, and
miR-451 (Table 3). The expression of miR-18a was re-
duced relative to the 5–21-week-old baseline group
when basophilic foci were present, i.e., significantly de-
creased expression was seen in the livers of 78 and
104 week old (1.7-fold decrease) females and not in
any of the males or 52-week-old female livers. The ex-
pression of miR-451 was significantly increased relative
to the 5–21-week-old baseline group when basophilic
foci were present, i.e., increased expression was seen in
the livers of 78 (1.8-fold increase) and 104-week-old

































































































































































































































































































































Kwekel et al. Biology of Sex Differences  (2017) 8:6 Page 14 of 21
(1.5 fold increase) females and not in any of the males
or 52-week-old female livers.
Table 2 also shows a substantial sex difference in the
prevalence of bile duct hyperplasia, with >80% of males
from 52 to 104 weeks of age having this histopathology.
It was not seen in females of 52 weeks of age, and oc-
curred in <20% of females of 78 and 104 weeks of age.
This lesion was not observed (0/12 males and 0/12
females at 6–7 week of age and 0/24 males and 0/24 fe-
males at 17–18 weeks of age) in contemporaneous stud-
ies at NCTR using F344 rats from the same colony and
living in the same environmental conditions at NCTR
[47]. Using the same analysis described above, the
expression of 2 miRNAs was found to associate with the
presence and absence of liver bile duct hyperplasia, miR-
99a and miR-203 (Table 4). The expression of both miR-
NAs was significantly increased in the livers of males
from 52 to 104 weeks of age relative to the expression in
the livers of the 5–21-week-old baseline group (1.6- to
2.5-fold). The expression of the 2 miRNAs was not sig-
nificantly changed in the livers of females of 52 to





Fig. 7 Histopathological assessment of sex-biased hepatic lesions. Liver sections (hematoxylin and eosin stained) from male and female rats at 52,
78, and 104 weeks of age were analyzed for the presence and/or severity of basophilic foci, hyperplasia of the bile duct, and vacuolization of
cytoplasm in hepatocytes. Representative images are shown of (a) female-biased basophilic focus from a 104-week-old female rat and (b)
normal liver from a similar area of a 104-week-old male rat; (c) male-biased hyperplasia of the bile duct (minimal) from a 52-week-old male rat
and (d) normal liver from a similar area of a 52-week-old female rat; (e) male-biased vacuolization of cytoplasm (mild) in hepatocytes from a
52-week-old male rat and (f) normal liver from a similar area of a 52-week-old female rat. Arrows point to histopathological features
Table 3 Correlation of miRNA expression with hepatic basophilic focia
Feature 52 week F 78 week F 104 week F 52 week M 78 week M 104 week M
Basophilic focusb No (0%)c Yes (38%) Yes (75%) No (0%) No (0%) No (0%)
miR-451 NS 1.8 1.5 NS NS NS
miR-18a NS 0.6 0.6 NS NS NS
F female, M male, NS not significant
aRelative expression values are the expression at the indicated ages relative to the average expression from 5 to 21 weeks of age for each sex independently
bFrom Table 2
cIncidence from Table 2
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Discussion
General trends in the expression of liver miRNAs during
the rat lifespan
Age and sex differences were evaluated independently to
identify liver miRNA expression changes during the rat
life span. The 214 DEMs included 212 miRNAs which
showed significant age differences and 65 miRNAs exhi-
biting significant sex differences. PCA (Fig. 1) and k-
means cluster analysis (Fig. 2) provided visualization of
the variability of individuals within age/sex groups, be-
tween groups, and among the individual miRNAs. Three
general observations followed from these analyses. First,
age plays a much larger role than sex in these hepatic
miRNA expression changes. Notable difference was ob-
served between 2-week-old animals and all subsequent
age groups in the PCA (Fig. 1), and aside from a small
sex difference observed between 2-week-old males and
females, no large-scale patterns of sex difference were
observed. Second, the notable separation in the PCA be-
tween 2-week-old animals and all subsequent age groups
was found to be caused by 38 two-week-specific miR-
NAs (Fig. 2 and Additional file 4). Third, aside from
miRNAs showing 2-week-specific expression, liver miR-
NAs exhibited relatively stable expression across both
sex and age, with >70% of the miRNAs having coeffi-
cient of variation <50% (Fig. 2). These differential
expression analyses and data visualization methods re-
vealed key insights into the data that helped focus path-
way analysis of the DEMs.
Sex-biased miRNAs linked to key liver pathways
Sex differences in miRNA expression were evaluated at
each age group (Fig. 3). The distribution of sex-biased
miRNAs identified in the liver showed a similar pattern
as the sex-biased miRNAs observed previously in kidney
tissues [34] from the same animal study. Both kidney
and liver showed significant sex-biased miRNA expres-
sion at 2 weeks of age and then again at ages of 15 weeks
and older, with a gap of no observed sex-biased miRNAs
between 5 and 6 weeks of age. Previously reported liver
mRNA expression study revealed a similar pattern of
sex-biased regulation, where 5- and 6-week-old rats
showed lower numbers of sex-biased mRNAs compared
to neighboring age groups, including the 8–21-week-old
groups [15]. This suggests either that sex-biased gene
expression change is not as crucial during the pubertal
developmental stage compared to other life stages, or
that the more subtle or fine-tuned miRNA regulation
may not be involved in the hormonally controlled sexu-
ally dimorphic expression changes that do exist during
this developmental time frame. Among the 65 sex-
biased DEMs, only 6 (miR-92a, miR-221, miR-374,
miR-505*, miR-532-3p, and miR-652) are encoded on
the X-chromosome. Four of these miRNAs exhibited
female-biased expression, and two exhibited male
biased expression (miR-92a and miR-221). miR-221
showed male-biased expression at 8, 15, and 21 weeks
of age, exhibiting a 14-fold difference in expression
(21 weeks) compared to females. This was the second
highest fold change difference among all sex-biased
miRNAs, with only male biased miR-183 having a
greater sex-biased expression (17-fold). As there was no
consistency in the sex-biased expression of the miRNAs, it
is not clear what role X-chromosome inactivation may
play in the control of sex-biased miRNA expression. No
miRNAs are encoded on the rodent Y-chromosome, and
only two miRNAs are Y-chromosome-encoded in humans
[55].
The miRNAs with the most consistent female-biased
expression were miR-29b (Fig. 3) and miR-152 (Fig. 3
and Fig. 4) with both showing an approximate 2-fold
higher expression in females than males at 15, 21, 52,
and 78 weeks of age. miR-29b is a key repressor of renal
and pulmonary fibrosis [56, 57] and has recently been
shown to inhibit hepatic fibrogenesis by directly target-
ing PIK3R1 and AKT3 in hepatic stellate cells [58]. The
role of the miR-29 family, including miR-29b, in fibrosis
disease has been recently reviewed and additional targets
appear to be collagens [59]. miR-152 is dysregulated in
rat models of NAFLD [60] and has been characterized to
act as a tumor suppressor [61]. Thus, these sexually di-
morphic miRNAs may play a role in differential suscep-
tibility to liver pathology and disease.
miRNAs showing the most male-biased expression in-
cluded miR-125b-5p, miR-99a*, miR-99a, miR-96, miR-
221, and miR-183 (Fig. 3). miR-125b-5p and miR-99a
showed the most consistent male-biased expression with
sex differences observed at 15, 21, 52, and 78 weeks of
Table 4 Correlation of miRNA expression with hepatic bile duct hyperplasiaa
Feature 52 week F 78 week F 104 week F 52 week M 78 week M 104 week M
Hyperplasia, bile ductb No (0%)c Minimal (25%) Minimal (13%) Yes (80%) Yes (88%) Yes (71%)
miR-99a NS NS NS 2.0 1.7 1.6
miR-203 NS NS NS 2.5 2.2 2.0
F female, M male, NS not significant
aRelative expression values are the expression at the indicated ages relative to the average expression from 5 to 21 weeks of age for each sex independently.
bFrom Table 2
cIncidence from Table 2
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age and fold changes ranging from 1.5 to 2.3. miR-99a*
exhibited similar significant male-biased expression of
1.7- to 2.3-fold at 15, 52, and 78 weeks of age. miR-
125b-5p and miR-99a are suggested to be co-expressed
in humans from chromosome 21 and play a role in vin-
cristine resistance of leukemia cells [62]. miR-221 and
miR-96 showed relatively larger sex differences over the
middle portion of the life span, with miR-221 expressed
at 3-to 14.3-fold higher levels in males than females
from 8 to 21 weeks of age, and miR-96 expressed at 2.2
to 7.2 higher levels in males than females from 21 to
78 weeks of age. miR-125b-5p and miR-221 play a role
in glioma carcinogenesis and have been recently pro-
posed as prognostic markers in assessing glioma tumors
[63]. The expression of miR-183 exhibited the largest
identified sex difference with 17.2-fold higher expression
in males compared to females at 104 weeks of age. miR-
183 and miR-96 are co-transcribed from the miR-183-
96-182 cluster found on chromosome 4 in rats and
chromosome 7 in humans [64], suggesting that post-
transcriptional processing may independently control
the expression of these miRNAs. MiR-183 has been
shown to function in a pro-oncogenic manner by sup-
pressing apoptosis and promoting proliferation in
esophageal cancer cells [65].
The expression of 30 miRNAs was sexually dimorphic
in the liver of adult (5 to 21 weeks of age) rats and there
is evidence that they are involved in the regulation of
149 mRNAs (Table 1). The top five molecular functions
associated with these mRNAs (cellular growth and pro-
liferation, cell death and survival, cellular development,
gene expression, and cell cycle) represent important
pathways whose disruption or modification may be ex-
pected to contribute to disease susceptibility. In fact, by
focusing on toxicological functions using the IPA data-
base, these mRNAs appear to be involved in multiple
processes related to liver disease, including necrosis,
proliferation, fibrosis, hepatocellular carcinoma, and
hyperplasia. Thus, this analysis suggests the sexually di-
morphic expression of miRNAs described in this study
may be reflective of sex differences in liver physiology
and disease susceptibility.
In older rats from 52 to 104 weeks of age, the hepatic
expression of 13 miRNAs was found to be sexually di-
morphic, with evidence that they are involved in the
regulation of 81 mRNAs (Table 1). The top five molecu-
lar functions associated with these mRNAs are identical
to those described above for the sexually dimorphic
mRNA targets in adults. Despite only seven sexually di-
morphic miRNAs being in common between the adult
and the old rats (miR-125b-5p, miR-152, miR-29b, miR-
374, miR-96, miR-99a*, and miR-99a), 91% (74/81) of
the mRNA targets in the old rats were also mRNA tar-
gets in the adult rats. This suggests that multiple
miRNAs target the same mRNAs resulting in a similar
impact on molecular functions. The toxicological func-
tions of these mRNAs, however, were more limited in
old rats compared to the adults. Only one significant
toxicological function was associated with the 81 mRNA
targets, liver necrosis. Thus, sexually dimorphic hepatic
miRNA expression in old rats is mostly a subset of that
in adults. The reduction in sexually dimorphic miRNA
expression seen in this study is consistent with the find-
ing of increased similarity of the male and female hep-
atic mRNA expression pattern at the oldest ages [15].
Two-week-specific miRNAs linked to Dlk1-Dio3 cluster
A prominent feature of the k-means cluster (Fig. 2 and
Additional file 4) is the high expression of 38 miRNAs
in clusters 2 and 3 at 2 weeks of age with no to little
expression at subsequent ages. A review of the miRNA
annotations which included chromosome locations
revealed a notable trend. Of the 38 miRNAs showing 2-
week-specific expression, 31 of them (81%) were
encoded on rat chromosome 6. Closer investigation re-
vealed that these chromosome 6-encoded miRNAs
were members of the delta-like 1 homolog-deiodinase,
iodothyronine 3 (Dlk1-Dio3) miRNA cluster. The con-
served DLK1-DIO3 miRNA cluster (located on 14q32
in humans) is the largest miRNA cluster in the human
genome and includes 54 encoded miRNAs [66]. The
Dlk1-Dio3 genomic region is an imprinted region con-
taining two differentially methylated regions which con-
trol its regulation [67]. A subset of miRNAs within the
Dlk1-Dio3 miRNA cluster, called the miR-379/410 clus-
ter (containing 38 miRNAs), has been shown to be
essential for neonatal liver energy homeostasis (hepatic
glucose and lipid metabolism) in mice [68]. miR-379,
miR-410, and 16 other miRNAs from this subcluster
were among the 2-week-specific miRNAs in our study
and were present in k-means clusters 2 or 3. Their
association with neonatal energy homeostasis is consist-
ent with their expression at 2 weeks of age, when ani-
mals are transitioning from maternal energy sources to
independent feeding. miRNA members of the Dlk1-
Dio3 cluster have also been shown to be activated in
embryonic stem cells [69] and positively correlate with
stem cell pluripotency and proliferation [70]. In a
mouse model of myocardial infarction, 29 miRNAs ori-
ginating from the Dlk1-Dio3 cluster were activated in
cardiomyocytes after induced tissue damage [71], sug-
gesting their role in tissue remodeling efforts to replace
damaged cardiac tissue. Taken together, these findings
suggest a role for Dlk1-Dio3 cluster miRNAs in liver
proliferation, differentiation, and energy homeostasis at
2 weeks of age, consistent with the potentially affected
pathways/functions (e.g., cellular growth and prolifera-
tion, cellular development, cellular growth and
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maintenance) identified from possible mRNA targets of
these miRNAs (Table 1).
In addition, the miRNAs expressed predominantly at
2 weeks of age have predicted mRNA targets that im-
pact the hematological system (Table 1). These three
target mRNAs (PRDM1, BCL6, and XBP1) are import-
ant transcription factors and regulators of B and T cell
differentiation, with all three encoded proteins inter-
acting with each other [72, 73]. This is consistent with
the mid-gestation to early juvenile expression of
hematopoiesis in the liver, which ends by postnatal
day 35 [74]. Thus, the high level expression of these
miRNAs at 2 weeks of age and the dramatically re-
duced levels by 5 weeks of age correlates with the
hematopoietic potential of the liver.
miRNA hepatic expression differences between adult
and old rats
The expression of a small number of hepatic miRNAs
significantly differed between adult (5–21 weeks of
age) and old (52–104 weeks of age) rats, 17 in males
and 14 in females. The expression of six (miR-29a,
miR-29b, miR-29c, miR-34a, miR-375, and miR-466b-
2*) was altered in both males and females (Table 1).
There were 109 potential target mRNAs for the 17
male miRNAs and 115 for the 14 female miRNAs,
with 77 (~42%) found in both males and females. This
high degree of overlap of the mRNA targets resulted
in the prediction of similar molecular function
changes as both males and females matured from
adults to old age. Three of the five most significantly
affected functions predicted to be affected included
cellular death and survival, cellular growth and prolif-
eration, and cell cycle. The miR-29 family and miR-
34a, whose expression was altered in both older males
and older females, are relatively well-studied miRNAs,
and their roles in cell proliferation and apoptosis are
established [75, 76]. In addition, the miR-29 family
members appear to play a significant role in the devel-
opment of liver fibrosis, possibly through the regula-
tion of collagen expression [59]. Thus, miRNA control
of important functions of liver maintenance appears to
be altered in aged males and females, and may con-
tribute to the age-associated susceptibility to liver dis-
ease, including fibrosis [77].
miRNA expression associates with histopathology
Tables 3 and 4 show the expression of specific miRNAs
associated with the presence or absence of specific liver
histopathology. Increased expression of miR-451 and de-
creased expression of miR-18a were associated with the
presence of hepatic basophilic loci, which are considered
pre-neoplastic lesions [53]. miR-451 has recently been
suggested as a prognostic biomarker of hepatocellular
carcinoma (HCC), with decreased expression in HCC
tissues correlating with advanced stage, metastasis, and
worse disease-free or overall survival [78]. In vitro stud-
ies demonstrated inhibition of cell growth, possibly
through direct suppression of the NF-κB pathway [79]
suggesting that the increased expression associated with
the presence of basophilic foci, observed in the present
study, may be a compensatory response to the pre-
neoplastic lesion. In addition, increased serum levels of
miR-451 were recently found in patients with NAFLD
[80]. Altered expression of miR-18a has also been impli-
cated in the development of HCC through modulation
of the estrogen receptor (ER) alpha protein [81] with in-
creased expression promoting the downregulation of the
ER alpha. Because the estrogen pathway appears to be
protective for HCC [82], this may be a key factor in
explaining the increased susceptibility of males to HCC.
The decreased expression of miR-18a found to be asso-
ciated with basophilic foci in the present study may,
again, be a compensatory response to the pre-neoplastic
basophilic foci.
Increased expression of both miR-99a and miR-203
was associated with the presence of hepatic bile duct
hyperplasia, a common aging lesion [83]. miR-99a ap-
pears to be a tumor suppressor in the liver [84] that
possibly acts through inhibition of the RNA-induced si-
lencing complex, Ago2 [85]. Several studies suggest that
miR-203 also acts as a tumor suppressor in the liver
[86–88] by inhibition of liver cell proliferation. Altered
expression of miRNA-203 has also been found to be as-
sociated with alcoholic steatohepatitis [89]. Thus, even
though the exact role of these miRNAs in the develop-
ment of hepatic basophilic foci and bile duct hyperpla-
sia is not known, as described above, these miRNAs
have been shown in a variety of in vitro, in vivo, and
bioinformatics studies to have a fundamental impact on
liver cell biology. Additional targeted studies will be
needed to evaluate these miRNAs as possible bio-
markers for these liver lesions and their possible roles
in development of age- and sex-dependent susceptibil-
ity to liver pathology.
Association of miRNA and mRNA expression
miRNAs have been shown to regulate protein expression
by a diverse set of mechanisms, some of which
destabilize mRNA targets [19]. Combining miRNA and
mRNA expression levels may allow a fuller understand-
ing of the influence of miRNAs on mRNA expression in
the rat liver. mRNA expression in the livers of rats from
this same study, measured by microarrays, has been pre-
viously published [15] and are available in the gene ex-
pression omnibus database (GSE21335). Preliminary
analysis of the expression of mRNA targets listed in
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Table 1 shows that 226 of the 464 mRNA targets (49%)
were expressed at detectable levels. Of these detectable
mRNA targets, the expression of an average of 26% of
mRNAs in each class was significantly (p < 0.05) changed
with an inverse relationship to the miRNA expression
change; that is, when the miRNA was significantly up-
regulated, the target mRNA was significantly downregu-
lated, or vice versa. Thus, the stability of a substantial
fraction of the detectable target mRNAs appears to be
directly affected by the miRNAs listed in Table 1.
The relationship between miRNAs and their targets,
however, is complex and not completely understood
[90]. For example, multiple miRNAs can affect a single
mRNA, and a single miRNA can affect multiple mRNAs.
Since the miRNAs may control protein expression by
mRNA degradation and/or inhibition of translation,
there may not be a direct inverse relationship between
miRNA levels and target mRNA levels. In addition, there
may be other factors that affect expression, such as
DNA methylation, transcription factors, and histone
modifications. Also, the current state of knowledge re-
garding miRNA-mRNA relationships in the liver is in-
complete. The relative lack of sensitivity of the older
microarray technology used to measure mRNA levels
[15] may be responsible for the low detectability of the
predicted target mRNAs. However, better quantitative
and sensitive methods, such as RNA-Seq, may allow
more accurate evaluation of the correlation of miRNA
expression with target mRNA expression. Additional
confirmatory computational and experimental analyses,
including protein quantitation, will be required to fully
understand the role of miRNAs and other gene regula-
tory mechanisms in the control of hepatic gene
expression.
Conclusions
As a key first step in understanding epigenetic mecha-
nisms that may influence sex- and age-related susceptibil-
ities to adverse liver events, genome-wide characterization
of liver miRNA expression profiles in both sexes during
the rat life span was carried out. miRNAs exhibited largely
stable expression between sexes and across the rat life
span with the exception of a conspicuous pattern of 38
miRNAs showing 2-week-specific expression. This pattern
at 2 weeks of age was explained in large part by co-
localization of 31 miRNAs to the Dlk1-Dio3 cluster on
chromosome 6. This cluster is putatively associated with
early developmental proliferation and differentiation, and
postnatal liver energy homeostasis, which is consistent
with the developmental events occurring in immature ani-
mals at 2 weeks of age. Pathway analysis of sex-biased
miRNAs in adult and old rats identified sexually di-
morphic molecular functions and toxicological functions
that may reflect sex differences in liver physiology and
disease susceptibility. The expression of specific miRNAs
(miR-451, miR-18a, miR-99a, and miR-203) was found to
associate with sexually dimorphic histopathology findings
of basophilic foci and bile duct hyperplasia. As rats mature
from adults to old-age, miRNAs involved in cell death, cell
proliferation, and cell cycle (miR-29 family and miR-34a)
were found to change expression. In addition, miR-29
family members may be involved in susceptibility to fibro-
sis. Thus, the expression of miRNAs involved in the con-
trol of important liver functions was shown to change
during the rat life span and between the sexes, and may
contribute to the age- and sex-associated susceptibility to
liver disease.
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